Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oligon catheter cuts infections:

This article was originally published in Clinica

Executive Summary

Implemed (US) has launched the Olimpicc central venous catheter (PICC), in the UK. The peripherally inserted catheter is made with Oligon anti-infection polymer technology. The company says nosocomial infections cost the US healthcare system over $11,000 million annually, while 3 million patients contract nosocomial infections every year in Europe. In developing countries this figure could be five to ten times higher. By preventing bacterial colonisation of PICCS, the "anti-infective" technology incorporated into Olimpicc "can mean improved patient outcomes and lower healthcare costs," Implemed claims. Launch of the Olimpicc throughout Europe, the Far East, and the US is also anticipated.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094522

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel